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Abstract
Purpose: Tumor infiltrating CD4+CD25+FoxP3+ regulatory immune cells (Treg) have been associated with impaired anti-
tumor immune response and unfavorable prognosis for patients affected by ovarian carcinoma, whereas CD8+ T-cells have
been found to positively influence survival rates in a large panel of solid tumors. Recently, density, location and tumor
infiltration patterns of the respective immune cell subtypes have been identified as key prognostic factors for different types
of tumors.
Patients and Methods: We stained 210 human ovarian carcinoma samples immunhistochemically for FoxP3 and CD8 to
identify the impact different immune cell patterns have on generally accepted prognostic variables as well as on overall
survival.
Results: We found that FoxP3+ cells located within lymphoid aggregates surrounding the tumor were strongly associated
with reduced survival time (P = 0.007). Central accumulation of CD8+ effector cells within the tumor bed shows a positive
effect on survival (P = 0,001).
Conclusion: The distribution pattern of immune cells within the tumor environment strongly influences prognosis and
overall survival time of patients with ovarian carcinoma.
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Introduction
Ovarian cancer has the highest mortality rate of all female
genital cancers. Over 200,000 women are diagnosed with primary
ovarian cancer every year [1–4]. Most of these cancers are
diagnosed at a late stage, over 75% of patients are staged FIGO III
or IV at first appearance. Overall five-year survival rates range
between devastating 25% and 49% [2,5–8]. Standard therapy,
cytoreductive surgery followed by platin and taxan chemotherapy,
initially leads to good response rates; however, in over 50% of the
cases the disease recurs within the following five years [9,10].
Generally accepted prognostic factors are optimal surgical
debulking, histological subtype, tumor grading and staging [2,6].
Nonetheless, these factors fail to predict overall survival rates
accurately, since patients with similar clinical and pathological
characteristics often differ widely concerning actual outcome and
survival.
The correlation between tumor-infiltrating lymphocytes and
prognosis of cancer patients has been investigated by numerous
papers throughout the past thirty years [11–13]. For ovarian
carcinoma Zhang et al. demonstrated as early as 2003 that CD3+
lymphocytes influence the progression-free and overall survival
rates of patients [9]. Studies have since aimed at identifying
methods to further depict the different cells that are involved in the
anti-tumor immune response. As a result, a subpopulation of T-
regulatory cells (Treg Cells) has been identified that plays a crucial
role in tumor-induced immune suppression [14,15]. The vast
majority of Tregs are characterized by expressing CD3, CD4,
CD25, the glucocorticoid- induced tumor necrosis factor receptor
family related gene (GITR), the cytotoxic T-lymphocyte antigen-4
(CTLA-4) and, most importantly, the transcription factor forkhead
box P3 (FoxP3) [16–19].
Treg cells are able to modulate the anti- tumor response of
CD8+ effector T-cells and are associated with poor prognosis in
ovarian carcinoma [20–24]. Similar results have been reported of
numerous other tumors, for example colon carcinoma [25] gastric
cancer [26] metastatic melanoma [27]. Curiel at al. showed that
human tumor Treg cells suppress tumor-specific T-cell immunity
and contribute to tumor growth in vivo. Treg cells were associated
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with a high mortality risk and reduced survival for patients with
ovarian carcinoma [15]. Other authors have focused on the
influence other subsets of T- lymphocytes have on the tumor
environment. High numbers of and intratumoral penetration by
CD8+ effector T-cells were found to slow down tumor growth and
have been identified as independent prognostic factors for serous
ovarian carcinoma [22]. On a similar note, a high CD8+ effector
T-cell-to-Treg cell ratio, rather than the absolute number of each,
has been suggested as an independent predictor of survival for
patients affected by ovarian carcinoma [14] as well as breast
cancer [28].
Apart from the determination of the mere presence of a distinct
cell type within the tumor environment, increasing evidence
suggests that the exact location and tumor infiltration pattern need
to be considered [23,27,29]. Other authors have claimed the
lymphoid clusters surrounding the carcinomata to be the actual
site of Treg cell activation. The accumulation of FoxP3+ cells
within lymphoid cell clusters was associated with a significantly
worse prognosis than samples with high numbers of Treg cells
[30–32].
This study is based upon the assumption that FoxP3 is a valid
Treg cell marker. However, there have been publications that
have questioned this assumption in the past [33,34]. There also
have been several reports of FoxP3 expression through tumor cells
themselves, which has been interpreted as a specific tumor escape
mechanism [35–37]. Some evidence also suggests that FoxP3+
Treg cell subpopulations may also be involved in tumor
suppressive functions [38,39]. The interaction of FoxP3 and the
transcription factor NFAT are subject to further investigation to
ultimately understand FoxP3 function [40]. Moreover, other
immune cells are known to be able to exert immunsuppresive
mechanisms, but do not express FoxP3 [41,42,43]. However, the
single legitimate Treg cell marker still remains to be discovered
Table 1. Patient and tumor characteristics.
n
Number of Samples 210
Age (Mean/Range) 60.77(27–87)
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and for now FoxP3 remains to be the most established and
understood Treg cell marker we know [17,27,44–47].
Material and Methods
Patient characteristics
210 tumor tissue samples were selected from the archives of the
Institute of Pathology of the Ludwig-Maximilians University,
Munich, Germany. All patients had undergone debulking surgery
at the Department of Obstetrics and Gynecology, Maistrasse,
University Clinic Munich, between 1989 and 2002. The patients
were between 27 and 87 years of age at diagnosis, with a median
age of 60.1. Tumors were graded according to the Silverberg
grading system. Most tumors were graded class 3+4 (62.2%) and
only very few class 1 (2.96%). Only samples classified as stage III
cancers, according to the International Federation of Gynecology
and Obstetrics (FIGO), were included. All histological types of
epithelial ovarian carcinoma were selected, but the serous (77.1%),
endometroid (8.1%) and adenocarcinoma NOS (5.3%) were by far
the most commonly represented types (Table 1).
Histology and immunohistochemistry
The formalin-fixed, paraffin- bedded blocks were cut into
approximately ,2 mm thick slices and mounted on SuperFrost
Plus microscope slides (Menzel Gläser, Braunschweig, Germany).
After deparaffinization and rehydration, sections were immersed
into Dako Target Retrieval solution (Dako North America Inc.,
Carpinteria, USA), pH 6, 1:10, incubated at 97uC–99uC at 750
Watt for 2x 15 minutes, and allowed to cool to room temperature
for 20 minutes. Endogenous peroxidase activity was blocked by
10-minute incubation in 7.5% hydrogen-peroxide solution (Hy-
droxen Peroxide Solution, Sigma Aldrich Co., Munich, Germany).
Immunohistochemical staining for FoxP3 was performed accord-
ing to standard procedure using MACH-3 mouse alkalic
phosphatase polymer detection kit from Biocare Medical Systems
(Concord, USA). The slides were incubated with monoclonal
mouse antibody. Chromogen Red (Dako North Amerika Inc.,
Carpinteria, USA) was used as chromogen for FoxP3 staining, and
lastly hematoxylin counterstaining was done (Vector Laboratories,
Burlingam, USA). An independent set of slides was selected to
perform immunhistochemical staining for CD8+ T-cells. These
specimens were automatically stained using Ventana Benchmark
XT according to standard operating procedure with monoclonal
mouse antibody (Anti- Human CD8- AB-1 Antigen, Vision,
Fremont, USA). Additional single serial staining was performed for
CD4 and CD20 automatically using Ventana Benchmark XT
with monoclonal mouse antibody according to the XT ultraView
DAB procedure (Table 2).
Cells were first quantified by counting absolute numbers of 100
power fields per specimen (two independent investigators). After
adequate group boundaries were defined, all remaining 110
specimens, as well as the initial 100 samples, were reevaluated
semi-quantitatively. At least 35–40 high power fields were counted
at 20- or 40-fold magnification (Axiovert Inverse Microscope, Carl
Zeiss, Jena, Germany). The amount of cells was categorized
according to a specific scoring system (Table 3).
Preferred cell location (central vs peripheral) and finally, the
infiltration of immune cells into the tumor tissue were checked (no
infiltration vs. infiltration). Per definition, only cells surrounded by
at least three tumor cells were counted as infiltrating the tumor.
Statistical analysis
Statistical analysis was done by Superior Performance Software
Systems Statistics Software (SPSS). Correlations between clinico-
biological data and the FoxP3+ and CD8+ cell content were
determined using a x2 test. Survival curves were plotted using the
Kaplan-Meier method and compared using the log-rank test.
Multivariate analyses of prognostic factors for survival were
performed using a Cox Proportional Hazard Model.
Ethics Statement
Following the requirement of an ethics statement for publication
of our manuscript in your journal, we would like to declare that
the presented data were the result of a retrospective analysis on
anonymized biopsy material. The material was sampled for
diagnostic purposes. At all times we acted in accordance with the
legal requirements concerning confidential medical communica-
tion as well as the data protection act. Consequently, we were sure
before starting our investigation in 2009 that consulting the
Institutional Review Board of out University was not required.
Results
a) Amount, Location, Infiltration of CD8+ and FoxP3+
CD8+ and FoxP3+ cells were detected in nearly all specimens,
with CD8+ and FoxP3+ staining exclusively found on lymphocytes
(Table 4). The amount of CD8+ cells mostly varied between 5 and
25 cells per field. In 53.8% of the examined specimens, CD8+ cells
mainly accumulated in the peripheral stroma surrounding the
Table 3. Scoring System.
Group1 Group2 Group3 Group4
CD8 0–4 5–14 15–24 .25
FoxP3 0–4 5–14 15–24 .25
doi:10.1371/journal.pone.0111757.t003
Table 4. Amount of cells.
Group1 Group2 Group3 Group4 Missing
CD8 54 (25.7%) 78 (37.1%) 68 (32.4%) 8 (3.8%) 2 (1%)
FoxP3 65 (31.0%) 50 (23.8%) 59 (28.1%) 27 (12.9%) 9 (4.3%)
doi:10.1371/journal.pone.0111757.t004
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tumor tissue and in 46.2% they spread equally throughout the
tissue (Figure 1). A mere 60.1% of cases showed tumor-infiltrating
CD8+ cells (Figures 2 and 3).
FoxP3+ cell count mainly ranged between 5 and 25 cells per
field as well, but overall more FoxP3+ than CD8+ cells were
counted in the specimens. Moreover, FoxP3+ cells accumulated
relatively more often within the centre of the specimen than in the
peripheral stroma (63.3%) (Figures 4 and 5). FoxP3+ cells usually
infiltrated the tumor tissue (94.4% positive tumor infiltration)
(Figure 6) (Tables 5 and 6).
Figure 2. CD8+ T-cells infiltrating tumor tissue. Microscope: Carl Zeiss, Jena, Germany, 20-fold magnification, room temperature, Adobe
Photoshop.
doi:10.1371/journal.pone.0111757.g002
Figure 1. CD8+ T-cells: Location.
doi:10.1371/journal.pone.0111757.g001
Figure 3. CD8+ T-cells: Tumor infiltration pattern.
doi:10.1371/journal.pone.0111757.g003
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b) Correlation analysis
The amount of CD8+ cells within the specimen strongly
correlates with the amount of FoxP3+ cells (p = 0.0001). Also, high
numbers of CD8+ T-cells are positively linked to tumor infiltration
of CD8+ cells (p = 0.001).
Increased numbers of FoxP3+ cells are associated with tumor
infiltration of FoxP3+ cells, thus implying a benchmark number of
Treg cells necessary for invasion into the tumor tissue (p = 0.001).
Moreover, the ratio of CD8+T-cells to FoxP3+ cells strongly
correlates with FoxP3+ cell location: a high CD8-to-FoxP3 ratio is
associated with peripheral location of FoxP3+ cells. They mainly
accumulate in lymphoid clusters surrounding the tumor. A low
CD8+ to-FoxP3+ ratio, however, is associated with tumor
infiltration of FoxP3+ cells. As soon as FoxP3+ cells outweigh
CD8+ cells, they will infiltrate into the tumor and spread
throughout the specimen.
Figure 4. FoxP3+ cells mainly accumulate centrally. Carl Zeiss, Jena, Germany, 20-fold magnification, room temperature, Adobe Photoshop.
doi:10.1371/journal.pone.0111757.g004
Figure 5. FoxP3+ cells: Location.
doi:10.1371/journal.pone.0111757.g005
Figure 6. FoxP3+ cells: Tumor infiltration pattern.
doi:10.1371/journal.pone.0111757.g006
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The correlation tables reveal a significant relationship between
‘‘grading’’ level and FoxP3+ cell density, implying that high levels
of FoxP3+ Treg cells are associated with significantly worse
grading according to the Silverberg grading classification scheme
(p = 0.004). This relationship is further emphasized by the negative
correlation found between the CD8-to-FoxP3+ cell ratio and
grading. Relatively low levels of CD8+ effector cells in comparison
to FoxP3+ Treg cells are significantly associated with lower
histological tumor grading (p = 0.001). Surprisingly, the parameter
of ‘‘location of FoxP3+ cells’’ individually influences survival time
(p = 0.007). Peripheral accumulation of Treg cells in lymphoid
clusters surrounding the tumor bed is consequently associated with
significantly less overall survival time than central accumulation
within the tumor bed.
In order to quantify the influence generally accepted prognostic
factors have on the prognostic model, statistical analysis was also
done for common prognostic variables. ‘‘Age’’ (p = 0.001),
‘‘grading’’ (p = 0.001) and ‘‘optimal surgical debulking’’
(p = 0.007) showed significant effects on survival time, while
neither the ‘‘employed neo-adjuvant therapy’’ nor ‘‘histological
subtype’’ did. The lack of influence the parameter ‘‘histological
subtype’’ shows is probably due to the lack of homogeneity of
histological subtypes within the population.
c) Cox Proportional Hazard Model
Using the Cox Proportional Hazard Model eliminated the
statistical effects of the prognostic factors age, grading and surgical
debulking. Three major individual prognostic factors for patients
with ovarian carcinoma were then revealed. Firstly, the location of
CD8+ T-cells within the specimen is an individual prognostic
factor for patients with ovarian carcinoma (p = 0.001). Centralized
accumulation of CD8+ effector cells in the tumor bed leads to
prolonged survival time. Secondly, peripheral accumulation of
FoxP3+ Treg cells in lymphoid clusters is a strongly significant
negative prognostic factor for patients suffering from ovarian
carcinoma (Table 7).
d) Kaplan-Meier Curves and Log-Rank Test
The significant influence the location of CD8+ T effector cells as
well as the location of FoxP3+ Treg cells within the specimen have
on the overall survival time of a patient was reinforced by using the
Kaplan-Meier Model (p = 0.049 and p = 0.056) (Figures 7 and 8).
Discussion
This study examined the tissue of 210 patients with ovarian
carcinoma for the infiltration of CD8+ effector T-cells and FoxP3+
T regulatory cells (Treg). In addition to the calculation of the
respective frequencies, special attention was paid to the exact
locations of the immune cells and to their capacity to infiltrate into
the tumor bed. In order to adjust for known prognostic factors,
multivariate analysis was done using the Cox Proportional
Hazards Model introducing classical histophathological parame-
ters such as grading, age at diagnosis, and surgical debulking
success.
The current paradigm in tumor immunity suggests that tumor-
associated antigens are captured by professional dendritic cells,
which in turn prime naive T-cells to become antigen-specific anti
tumor effector T-cells [48]. Ultimately, a large number of
activated CD8+ effector T-cells should thus be able to attack the
tumor tissue and eradicate the tumor. Unfortunately, as tumors
actively fight to suppress effector cell function by producing
immunosuppressive factors such as IL-10, TGFß, and VEGF,
effective tumor eradication is rarely successful [49–52]. Moreover,
the immunosuppressive function Treg cells exert on CD4+ and
CD8+ T-cells have been identified as a crucial variable limiting an
effective anti- tumor immune response. Yet, the mechanisms of
suppression Treg cells make use of still remain to be fully
understood.
The results of our study signify that the invasion of great
numbers of CD8+ T effector cells is in fact one of the major
prognostic factors for patients with ovarian carcinoma. This has
previously been suggested for ovarian carcinoma as well as breast
cancer by numerous authors [10,14,28,53], but the focus of
attention has so far not been placed on the location of the cells
within the examined material, but on the mere amount of CD8+
T-cells and the ratio of CD8+ to other immune cells, respectively.
The location, however, seems to be of greatest importance for an
effective tumor attack. High numbers of CD8+ effector cells are
also strongly associated with lower levels of histopathological
grading, which strengthens the case that sufficient numbers of
CD8+ T-cells within the tumor bed are actually able to keep
tumor growth in check.
FoxP3+ Treg cells were mainly present within the tumor area,
but less frequently they gathered in groups surrounding the tumor.
In order to determine what cell types comprise these aggregates of
immune cells we performed additional single serial staining for
CD4 and CD20. We thereby could identify these peripheral
Table 5. Localisation of cells.
Central. = Peripheral Central,Peripheral Missing
CD8 96 (45.7%) 112 (53.3%) 2 (1%)
FoxP3 57 (27.1%) 33 (15.7%) 120 (57.1%)
doi:10.1371/journal.pone.0111757.t005
Table 6. Tumor infiltration of cells.
Tumor not Infiltrated Tumor infiltrated Missing
CD8 83 (39.9%) 125 (59.5%) 2 (1%)
FoxP3 5 (2.4%) 85 (40.5%) 120 (57.1%)
doi:10.1371/journal.pone.0111757.t006
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immune cell aggregates as lymphoid structures. FoxP3+ expression
in these lymphoid aggregates surrounding the tumor bed was
found to be an independent prognostic factor for patients with
ovarian carcinoma. Therefore, the presence of Treg cells within
these lymphoid infiltrates is associated with a significantly higher
risk of relapse and death. This finding has previously been
reported for patients with breast carcinoma [31] as well as for
follicular lymphoma [30]. Supposedly, this clinical observation
results from the selective activation of Treg cells within these
aggregates surrounding the tumor bed. Here, mature dendritic
cells present tumor-specific antigens to peripheral naive FoxP3+
Treg cells, which then proliferate in situ and are thereafter capable
of suppressing the anti tumor immune response of CD8+ effector
T-cells through heterogeneous mechanisms including IL-10 and
TGF-ß [32,48,51,54]. This thesis was further strengthened by
Gobert’s finding that only Treg cells located in these lymphoid
aggregates actually expressed activation markers such as HCA-
DR, GITR and ICOS, while FoxP3+Treg cells located within the
tumor tissue itself did not [31]. Previously, other authors have
reported the expression of B7-H1 by dendritic cells within these
aggregates, a receptor by which dendritic cells are able to prime
the conversion of peripheral T-cells to functional Treg cells [48].
The accumulation of FoxP3+Treg cells within lymphocyte clusters
surrounding the tumor, as well as abundant B7-H1 expression
within this region, have lately also been reported for patients with
prostate cancer [29]. Thus, it seems to be crucial not only to
determine the density of FoxP3+ cells, but their exact location in
the examined tissue. In order to influence the tumor microenvi-
ronment, the B7-H1 receptor seems to be one key mechanism
which controls Treg cell activation.
On a different note but in accordance with the findings of this
study, Jaffee et al. revealed that CD8+FoxP3+ cells are present in
tumors only if there is an existing pool of tumor-rejecting effector
CD8+ T-cells. Therefore, the accumulation and likely the tumor
infiltration of FoxP3+ T-cells mark the presence of tumor-rejecting
antigen-specific CD8+ T cells, which in turn serves as a marker for
an effective T-cell response [55]. Similar results were presented by
Nishikawa et al. as well as Rahir et al. [56,57]. Overall, recent
Table 7. Biomarkers and their influence on overall survival.
Biomarkers No. Positive (%) Overall survival (P) Morphological pattern
CD8+ cells
central 46.2 0.049 Central Location of CD8+ cells increases survival
peripheral 53.8 NS
FoxP3+ cells




Figure 7. Log-Rank-Test CD8+. Central accumulation of CD8+ T cells is significally associated with survival (p = 0.049).
doi:10.1371/journal.pone.0111757.g007
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data is suggesting that a unique effector subset of FoxP3+ cells may
exist which influences the tumor microenvironment in a favorable
way and contributes to overall antitumor response. Given the
multifaceted influence Tregs play in cancer progression, further
research is urgently needed to develop targeted therapies.
Acknowledgments
We thank Andrea Sendelhofert and Anja Heier for expert technical
assistance.
Author Contributions
Conceived and designed the experiments: CJLH DM DA SE. Performed
the experiments: CJLH DM. Analyzed the data: CJLH DM JE.
Contributed reagents/materials/analysis tools: DM TK DA SE. Contrib-
uted to the writing of the manuscript: CJLH DM DA.
References
1. WHO WHO (2009) World Health Observatory. Geneva: World Health
Organization.
2. Fachgesellschaften AdWM (2007) Diagnostik und Therapie maligner Ovar-
ialtumoren. AWMF.
3. Tavassoli FA, Devilee P, editors (2004) Pathology& Genetics: Tumours of the
Breast and Female Genital Organs: World Health Organization Classification of
Tumours.
4. Koch-Institut R (2010) Verbreitung von Krebserkrankungen in Deutschland.
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